Research programme: anti-estrogen compounds - AVAX Technologies

Drug Profile

Research programme: anti-estrogen compounds - AVAX Technologies

Alternative Names: 6-MCDF; Alkyl-PCDFs research programme - AVAX Technologies; Anti-estrogen technologies research programme - AVAX Technologies; Polychlorodibenzofurans research programme - AVAX Technologies

Latest Information Update: 16 Mar 2007

Price : $50

At a glance

  • Originator Texas A&M University
  • Developer AVAX Technologies; Texas A&M University
  • Class
  • Mechanism of Action Estrogen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 05 Jul 2005 AVAX is exploring opportunities to license out its compounds from this programme to another company
  • 12 Nov 2001 A preclinical study has been added to the Cancer pharmacodynamics section
  • 26 Feb 2001 Preclinical development for Cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top